Supernus Pharmaceuticals INC (SUPN) Stake Maintained by Rice Hall James & Associates Llc

May 19, 2017 - By Marguerite Chambers

Rice Hall James & Associates Llc increased its stake in Supernus Pharmaceuticals Inc. (SUPN) by 79.02% based on its latest 2016Q4 regulatory filing with the SEC. Rice Hall James & Associates Llc bought 477,498 shares as the company’s stock 0.00% . The institutional investor held 1.08 million shares of the health care company at the end of 2016Q4, valued at $27.31M, up from 604,242 at the end of the previous reported quarter. Rice Hall James & Associates Llc who had been investing in Supernus Pharmaceuticals Inc. for a number of months, seems to be bullish on the $1.75 billion market cap company. The stock rose 1.34% or $0.45 reaching $34.1 per share. About 346,800 shares traded. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

Rice Hall James & Associates Llc, which manages about $1.51 billion and $1.98B US Long portfolio, decreased its stake in Advanced Energy Industries In (NASDAQ:AEIS) by 88,347 shares to 293,422 shares, valued at $16.07 million in 2016Q4, according to the filing. It also reduced its holding in Silicon Laboratories Inc. (NASDAQ:SLAB) by 95,446 shares in the quarter, leaving it with 261,940 shares, and cut its stake in Tetra Tech Inc. (NASDAQ:TTEK).

Investors sentiment decreased to 0.91 in Q4 2016. Its down 0.13, from 1.04 in 2016Q3. It dived, as 19 investors sold SUPN shares while 89 reduced holdings. 37 funds opened positions while 61 raised stakes. 44.31 million shares or 1.54% less from 45.01 million shares in 2016Q3 were reported. Teachers Retirement Sys Of The State Of Kentucky owns 15,400 shares. Geode Capital Management Ltd Liability Company has invested 0% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Prudential has 0.01% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 273,599 shares. Cap Mngmt Corporation Va reported 1.02% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Moreover, Umb Natl Bank N A Mo has 0.02% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Picton Mahoney Asset Management invested in 0.01% or 6,400 shares. Royal Bancorporation Of Canada invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Shell Asset Management Company reported 54,418 shares. D E Shaw & Com holds 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 22,594 shares. 55,600 are held by 1832 Asset Mgmt L P. Trexquant Investment Ltd Partnership holds 0.09% or 22,000 shares in its portfolio. Citadel Advsr Ltd Llc owns 0% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 40,122 shares. Credit Suisse Ag, a Switzerland-based fund reported 78,638 shares. 316,430 are held by State Common Retirement Fund. Sheets Smith Wealth Mgmt reported 0.26% stake.

More notable recent Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news were published by: which released: “Supernus Pharmaceuticals Offers A Rare Opportunity For Investors” on January 05, 2017, also with their article: “Supernus Pharmaceuticals: The Investment Case Improves” published on December 15, 2016, published: “Supernus: Label Expansion, Trokendi Settlement Catalysts For More Upside” on March 16, 2017. More interesting news about Supernus Pharmaceuticals Inc (NASDAQ:SUPN) were released by: and their article: “Supernus Is Moving In The Right Direction” published on January 26, 2017 as well as‘s news article titled: “Supernus Pharmaceuticals’ (SUPN) CEO Jack Khattar on Q3 2016 Results …” with publication date: November 18, 2016.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage

Among 4 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Supernus Pharmaceuticals had 7 analyst reports since August 26, 2015 according to SRatingsIntel. The rating was downgraded by Zacks on Wednesday, August 26 to “Hold”. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) earned “Outperform” rating by Northland Capital on Wednesday, October 28. The stock has “Buy” rating by Jefferies on Thursday, August 4. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) earned “Market Perform” rating by Northland Capital on Monday, July 18. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has “Outperform” rating given on Thursday, November 5 by Northland Capital. Piper Jaffray downgraded the stock to “Neutral” rating in Monday, July 18 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.